Valuation: GlucoTrack, Inc.

Market Cap 3.31M 2.89M 2.67M 2.45M 4.65M 319M 4.73M 31.88M 12.51M 156M 12.43M 12.16M 537M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -626K -547K -505K -464K -879K -60.22M -894K -6.03M -2.36M -29.43M -2.35M -2.3M -101M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day-0.02%
1 week+44.50%
Current month+65.83%
1 month+30.30%
3 months-29.07%
6 months-86.71%
Current year-86.33%
1 week 0.37
Extreme 0.3669
0.63
1 month 0.3
Extreme 0.301
0.63
Current year 0.29
Extreme 0.2907
4.24
1 year 0.29
Extreme 0.2907
14.14
3 years 0.29
Extreme 0.2907
5,939.99
5 years 0.29
Extreme 0.2907
46,800.05
10 years 0.29
Extreme 0.2907
468,000.47
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 63 2024-02-12
Date Insider Type Main position Quantity % Market Cap.
25-03-25Free

Director

4,490 0.0431%
25-03-24Others

Chief Executive Officer

42 0.0004%
25-03-24Free

Director

8,747 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
-0.02%+44.50%-90.29%-99.98% 3.31M
-0.17%+1.47%+3.16%+6.80% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.21B
-0.49%+1.48%+31.16%-6.46% 34.52B
+1.53%+3.11%+15.41%+58.54% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
+1.13%-3.11% - - 16.68B
-1.29%-0.52%+69.24%+117.60% 15.11B
+0.43%+3.34%+14.96%+17.46% 13.85B
+2.45%+3.99%+18.20%-30.12% 13.18B
Average +0.50%+5.30%+50.33%+75.89% 24.46B
Weighted average by Cap. +0.41%+0.83%+81.43%+121.61%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.76M -18.23M -16.75M -31.74M -2.17B -32.29M -218M -85.37M -1.06B -84.86M -83M -3.66B -19.39M -16.95M -15.64M -14.37M -27.24M -1.87B -27.7M -187M -73.25M -912M -72.81M -71.21M -3.14B
Net Debt -5.35M -4.68M -4.31M -3.97M -7.52M -515M -7.64M -51.51M -20.21M -252M -20.09M -19.65M -867M -3.94M -3.44M -3.18M -2.92M -5.53M -379M -5.63M -37.91M -14.87M -185M -14.79M -14.46M -638M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-07-15 US$0.5290 -0.02% 63,939,956
26-07-14 US$0.5291 +14.13% 39,545,723
26-07-13 US$0.4636 +11.07% 313,396
26-07-10 US$0.4174 +7.44% 425,328
26-07-09 US$0.3885 +6.12% 433,058
  1. Stock Market
  2. Stocks
  3. GCTK Stock